PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Mechanism of Action

PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system.

Typical Dosage (Research)

FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month.

Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.

Side Effects & Risks

Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.

Not recommended for use with alcohol. May cause significant nausea. Should not be used in patients with uncontrolled hypertension or cardiovascular disease.

Who Uses PT-141 (Bremelanotide)

Women with HSDD (approved use), researchers studying sexual function, individuals exploring libido enhancement.